Versameb AG

Swiss Biotech Association

Member

Versameb is developing a new technology platform for local protein delivery through mRNA induction in multiple disease areas, focusing first on regenerative medicine.

Products, services, technology

VERSAMEB's platform has produced candidates that are at an advanced preclinical stage.

Cooperation possibilities

Versameb is willing to exploit the potential of its proprietary platform with renowned pharmaceutical and biotech companies.

http://versameb.com
info@versameb.com
Prof. Friedrich Metzger

Location

Hochbergerstrasse 60C, 4057 Basel, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2017
Number of employees in Switzerland

1-9

Key business

Core competencies

You may also be interested in

Sintetica SA

Sintetica is a pharmaceutical company delivering injectable medicines to patients worldwide, through innovative science and excellence in development, production and marketing. The multicultural high-performing organization is built to support both the national growth and the global expansion.
Mendrisio

Member

Labatec Pharma SA

Labatec is a privately owned Swiss-based pharmaceutical company with more than 50 years of experience in delivering high quality products to the European and Emerging Markets. Covering both the hospital and retail sectors, we have a portfolio of over 65 products and a growing geographic footprint.
Meyrin

Member

GlycoEra AG

GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its propriety platform, the CustumGlycan Platform. GlycoEra develops first in class therapeutics in inflammatory disease, autoimmune disorder and immuno-oncology indications.
8952 Schlieren

Member